Second Opinion Periapical Radiolucency Contours

Pearl Inc.'s "Second Opinion Periapical Radiolucency Contours" is a computer-aided detection (CADe) software designed to assist dental professionals in identifying periapical radiolucencies on permanent teeth radiographs. It leverages computer vision and machine learning, specifically using bounding polygons, to highlight suspicious regions, demonstrating performance comparable to existing diagnostic aids.

Pearl Inc.'s "Second Opinion Periapical Radiolucency Contours" device has been reviewed and determined to be substantially equivalent to legally marketed devices. This computer-aided detection (CADe) software is intended to assist dental health professionals in identifying periapical radiolucencies on periapical radiographs of permanent teeth in patients aged 12 years or older, serving as a second reader. This determination means the device can be marketed, subject to compliance with general controls and other applicable regulations. The device employs computer vision and machine learning algorithms to highlight suspected regions of interest with bounding polygons. While its core technology and intended use align with existing CADe systems, including a previous version from Pearl Inc. and another company's product, it distinguishes itself by using polygons for detection rather than bounding boxes. Clinical testing, including a non-inferiority study, demonstrated that the device's performance in detecting periapical radiolucencies is comparable to its predicate. The device poses no direct safety hazards to patients, with primary risks related to false positives or negatives, emphasizing that clinicians should not rely solely on its output for decision-making. Manufacturers of such devices must adhere to ongoing requirements including annual registration, device listing, good manufacturing practices, and Unique Device Identification (UDI) rules.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the reported sensitivity and specificity of the device compared to its predicate and human experts, especially for subtle or early-stage periapical radiolucencies?; How does the device's use of bounding polygons, as opposed to bounding boxes, impact the precision and accuracy of detection, particularly in complex anatomical areas?; What specific machine learning models and training data were utilized, and how robust is the device's performance across diverse patient demographics and different imaging equipment?; Are there any long-term studies or post-market surveillance data available regarding the device's real-world impact on diagnostic accuracy, treatment planning, and patient outcomes in a clinical setting?; What are the established protocols or guidelines for integrating this CADe device into existing clinical workflows to optimize its utility while mitigating risks of over-reliance or alert fatigue?